Member Info for Doc3

Agreed.

And there is a very real risk they may not be able to get funding at all.

Be clear this is an existensial situation.

I really hope you’re right.

Yet I have no Idea how they would get to that without a partnership or substantial contract.

Hope is not a plan.

That’s fair Jelenko.

This stock has an Altman score of nearly -8. Bankruptcy risk is really high

Shareholders may be grateful for a raise on any terms because the alternative is insolvency. Even if 0.01p.

Absolutely.

At this rate it’ll be 0.01p by December. I can’t see what will stop it. They will issue 6 billion new shares with reverse split to get around the nominal value thing.

Total wipe out.

Dip? They’re all dips? It’s like an enormous chasm since July 2022.

The answer to that is 0.

It can be insolvent like so many before it.

Interesting.

What do you mean? What are implications?

Is this AI generated?

The whole thing is odd. Several billion dollar companies linked yet the SP held down by clear fund raise.

Anyone could decide to ring fence the IP at any point and just buy it.

There is hope. It’s tiny but you need hope.

To be fair less than I thought it would be

Reverse split. Very likely.

Again small shareholders lose.

One way to look at though is a charitable project. If you’ve invested it does at least look like you’ve helped advance cancer diagnostics. That’s good. And losses can be written off for tax.

All true.

It’s also a failing company with a going concern qualification.

Good luck.

You’re screaming into a void EC.

16% down.

Little investors likely to be wiped out.

Sobering and agree.

Ditto chat about CLN. They couldn’t be clearer, it’s equity raise.

Anyone still holding at raise will not own much company when dust settles.

To be fair this is normal on AIM. Small shareholders almost always lose.

There is hope. They could land a deal first: but hope is terrible terrible plan.

I don’t understand implications of what you’re saying?

Can you explain?

Good to see that update. A real endorsement of Parsortix.

I don’t really understand the fund raise. 6 million is only enough to extend run way by ?8 months max.

Which raises question what comes next. Do they think a big contract is inbound?

Https://scholar.google.com/scholar?scisbd=2&q=Parsortix+&hl=en&as_sdt=0,5#d=gs_qabs&t=1762175114389&u=%23p%3D-2hQBbClp_4J

The text of this is what references 40% of interview clinicians/ scientists thinking Parsortix is the future of ctc biopsy.

The remaining 60% was fragmented so Parsortix is the single system that seems to have future backing.

Not sure about Dutch bit, maybe.

I do think EC is onto something, I hadn’t quite realised that the first, and only mention of Immatics was at interim. Unsure why never announced,

It’s possible that this has brought revenue in low millions that came after June 2025. It’s possible that revenue will improve for second half. Particularly if immatics trials are going well.

Possible.

When did they start using it?

If so positive why did it not show in revenue figures to June?

I think Eid was a NED from Jan 23, at same time as Juliet Thompson and just after the disastrous business update.

Agree about KO.